C6888F62-AE14-4F73-A1B8-2CB81E2809FD
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 105.12483574244415
- age_years
- 25
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.519
- ALLOGRAFT_REJECTION+0.497
- NOTCH_SIGNALING+0.486
- INFLAMMATORY_RESPONSE+0.467
- INTERFERON_GAMMA_RESPONSE+0.463
- INTERFERON_ALPHA_RESPONSE+0.457
- IL6_JAK_STAT3_SIGNALING+0.448
- KRAS_SIGNALING_UP+0.439
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.437
- ANGIOGENESIS+0.421
Top 10 suppressed
- KRAS_SIGNALING_DN-0.259
- MYC_TARGETS_V2-0.052
- MYOGENESIS-0.039
- DNA_REPAIR-0.033
- SPERMATOGENESIS-0.029
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.020
- OXIDATIVE_PHOSPHORYLATION-0.019
- UV_RESPONSE_UP+0.024
- HEME_METABOLISM+0.042
- APICAL_SURFACE+0.062
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.902 |
| 2 | 12B24051-5657-45E8-9C64-5B6A06693471 | — | — | 0.901 |
| 3 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.899 |
| 4 | TCGA-49-6745-01A-11R-1858-07 | — | cohortA1 | 0.895 |
| 5 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.895 |
| 6 | TCGA-CN-4734-01A-01R-1436-07 | — | — | 0.894 |
| 7 | SRR934816 | — | — | 0.893 |
| 8 | TCGA-98-7454-01A-11R-2045-07 | — | cohortMD2 | 0.893 |
| 9 | MDT-AP-0731 | Med | Medulloblastoma | 0.890 |
| 10 | BS_VP5Y45Z7 | pilocytic astrocytoma | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.519 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.497 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.486 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.467 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.463 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.457 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.448 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.439 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.437 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.421 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.404 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.399 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.385 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.366 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.364 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.314 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.298 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.264 | Inavolisib | — uncovered |